The company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, has recently demonstrated a 60% objective response rate in metastatic malignant melanoma.
Nordic Life Science asked the Chief Medical Officer (CMO) of Ultimovacs, Jens Bjørheim, about the n